Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Acquired von Willebrand syndrome associated with monoclonal gammopathy: a single-center study of 36 patients.

Voisin S, Hamidou M, Lefrançois A, Sigaud M, Mahé B, Trossaërt M.

Medicine (Baltimore). 2011 Nov;90(6):404-11. doi: 10.1097/MD.0b013e3182397166.

2.
4.

[Acquired von Willebrand syndrome].

de Lange DW, Fijnheer R, Wittebol S.

Ned Tijdschr Geneeskd. 2003 Sep 13;147(37):1808-11. Dutch.

PMID:
14526622
5.

Clinical significance of inhibitors in acquired von Willebrand syndrome.

Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T.

Blood. 1998 May 15;91(10):3623-9. Erratum in: Blood 1999 Jan 1;93(1):413.

6.

Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.

Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z.

Best Pract Res Clin Haematol. 2001 Jun;14(2):401-36. Review.

PMID:
11686107
8.

Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)-associated acquired von Willebrand syndrome.

Grimaldi D, Bartolucci P, Gouault-Heilmann M, Martin-Toutain I, Khellaf M, Godeau B.

Thromb Haemost. 2008 Apr;99(4):782-3. doi: 10.1160/TH07-07-0456. No abstract available.

PMID:
18392339
9.

Acquired von Willebrand syndrome: features and management.

Mohri H.

Am J Hematol. 2006 Aug;81(8):616-23. Review.

10.
11.

Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome.

Federici AB.

Hum Immunol. 2005 Apr;66(4):422-30. Review.

PMID:
15866707
12.

Effectiveness of high-dose intravenous gamma globulin therapy in acquired von Willebrand's disease.

van Genderen PJ, Michiels JJ, Bakker JJ, van 't Veer MB.

Vox Sang. 1994;67(1):14-7. Erratum in: Vox Sang 1994;67(3):322.

PMID:
7975445
13.
14.
15.

Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.

Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA.

Blood Coagul Fibrinolysis. 2009 Mar;20(2):89-100. doi: 10.1097/MBC.0b013e3283254570. Review.

PMID:
19786936
16.

Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.

Sucker C, Michiels JJ, Zotz RB.

Acta Haematol. 2009;121(2-3):177-82. doi: 10.1159/000214858. Epub 2009 Jun 8. Review.

PMID:
19506364
17.

Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias.

Dicke C, Schneppenheim S, Holstein K, Spath B, Bokemeyer C, Dittmer R, Budde U, Langer F.

Ann Hematol. 2016 May;95(6):945-57. doi: 10.1007/s00277-016-2650-x. Epub 2016 Apr 4.

PMID:
27040683
18.

Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.

Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.

Semin Thromb Hemost. 2006 Sep;32(6):636-45. Review.

PMID:
16977574
19.

Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.

Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.

Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. Review.

PMID:
17164493
20.

Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).

Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.

Blood Coagul Fibrinolysis. 2004 Jun;15(4):323-30.

PMID:
15166918

Supplemental Content

Support Center